SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on the development of novel cancer immunotherapies. It specializes in creating treatments that harness the body’s immune system to fight cancer, with a primary focus on its lead product candidate, galinpepimut-S, which is designed to treat various types of cancer. The company operates in the biotechnology sector and targets healthcare providers and patients in the oncology market, primarily in the United States.
